Professional Documents
Culture Documents
Content
What is PD/PD?
Time-dependent Concentration-dependent
effective it must first reach the active site of an organism in a sufficient quantity and remain there for an adequate length of time to interrupt normal life functions of the organism.
9/19/2013
PHARMACODYNAMICS: Describes the characteristics of the interaction between a drug and its active site including pharmacologic action.
9/19/2013
Adapted from: Craig WA. Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men. CID, Jan 1998; 26:1-12.
9/19/2013
PHARMACOKINETICS PARAMETERS
Absorption Not applicable to intravenous drugs Distribution Where the drug goes to in the body Apparent volume of distribution (Vd) Metabolism
PK/PD Parameters
5 Concentration 4
3
2 1 0 0 2 4 6 8 Time (h) 10 12 14
AUC
The rate and/or extent of bactericidal activity increase with increasing antimicrobial concentrations. The goal of a dosing regimen is to optimize the peak:MIC. (Peak:MIC of 10 to 20 is desired)
1.0E+07 1.0E+05
1.0E+03 1.0E+01 0 5
Control 0.5xMIC 4xMIC
10
0.125xMIC 1xMIC 8xMIC
15
0.25xMIC 2xMIC 16xMIC
20
1.0E+07
1.0E+05
1.0E+03
1.0E+01 0 10
Control 4xMIC
20
0.5xMIC 8xMIC
30
MIC 16xMIC
40
2xMIC 32xMIC
50
Organism kill
Therapeutic goal
Drusano, Craig. J Chemother 1997;9:3844; Drusano, et al. Clin Microbiol Infect 1998;4(Suppl. 2):S27S41; Vesga, et al. 37th ICAAC (1997)
Decreased Resistance
Faster Sterilization
Optimising outcomes requires more than just selecting the right drug
Drug Right drug + Right dose
Infection
Bacteria
Host defences
Host
EUCAST Approach
PK/PD Breakpoints (Clinical, non-species) Definition of susceptible
A microorganism is defined as susceptible by a level of antimicrobial activity associated with a high likelihood of therapeutic success
Setting breakpoints involves clinical results from various types of study, wildtype MIC distributions for relevant species of organisms, antimicrobial dosing and PK/PD of antibiotic
Ref: Mouton JW et al. The role of PK/PD in setting clinical breakpoints: the EUCAST approach. Clin Microb Infect 2012; 18: E37-E45.
Ceftazidime
Ref: Mouton JW et al. The role of PK/PD in setting clinical breakpoints: the EUCAST approach. Clin Microb Infect 2012; 18: E37-E45.
Ceftazidime
Ref: Mouton JW et al. The role of PK/PD in setting clinical breakpoints: the EUCAST approach. Clin Microb Infect 2012; 18: E37-E45.
Bioavailability
EFFECT OF PK ON AST
Bioavailability (F)
Measurement of the rate & extent to which a drug reaches the systemic circulation (Absorption) Intravenous 100% Oral 55% to >90% Highly variable due to multiple factors e.g.
GI transit time Drug-drug and drug-food interaction
Cefuroxime axetil
F = 36% (fasting) to 52% (post-meal)1 Acetoxyethyl-ester prodrug EUCAST2 for S. pneumoniae For IV, S: < 0.5 mcg/ml; R: >1 mcg/ml For PO, S: < 0.25mcg/ml; I: > 0.5 mcg/ml
Ref: 1. Finn, A., A. Straughn, M. Meyer, and J. Chubb. 1987. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm. Drug Dispos. 8:519-526. 2. EUCAST Ver 2.0
Penicillin
F = 60% to 73% Affected by gastric pH as natural penicillins are susceptible to hydrolysis Pen-G IV: S < 2; R > 8 Pen V PO: S < 0.06; R > 2
Distribution
EFFECT OF PK ON AST
Distribution (Vd)
Central i.e. blood & highly perfused organs (heart, kidneys) Peripheral
Tissue Muscle Bone CSF Eye
Protein binding
Tissue penetration
Drug must get to where it is needed in order for it to exert its action.
Streptococcus
Meningitis 1. Cefepime S < 0.5; R > 2 2. Ceftriaxone S < 0.5; R > 2 3. Penicillin S < 0.06; R > 0.12 Non-meningitis 1. Cefepime S < 1; R > 4 2. Ceftriaxone S < 1; R > 4 3. Penicillin S < 2; R > 8
Ref: Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid / blood-brain barrier for treatment of central nervous system infections. Clin Micro Rev 2010; p858-883.
EFFECT OF PD ON AST
Lay Definitions
Static prevents microorganism growth Cidal kills microorganisms
Microbiological Definitions
Minimum bactericidal concentration (MBC)
lowest concentration of an antibacterial agent that either totally prevents growth or results in a >99.9% decrease in the initial inoculum (i.e., a 3-log10 reduction in colony-forming units [cfu]/mL) on subculture.
Clinical Utility
Lack of strong correlation between clinical efficacy and microbiologic definition One abx class that is generally bactericidal can be bacteriostatic if used at low concentrations or against particular microbes ? Usefulness of performing MBC routinely.
Impact on AST
Thank you!